You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Brain metastases from Non-Small Cell Lung Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Small Cell Lung Cancer, Brain Metastases Trial (Cadonilimab)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Brain Metastases
  • (no location specified)
Apr 2, 2023

NSCLC Metastatic Trial in Shanghai (Almonertinib, SBRT)

Recruiting
  • Non-small Cell Lung Cancer Metastatic
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 23, 2023

NSCLC Trial in Pittsburgh (Tiragolumab, Atezolizumab, Pemetrexed)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Feb 16, 2023

Non Small Cell Lung Cancer Metastatic, Brain Metastases, Adult, KRAS G12C Trial (JDQ443)

Not yet recruiting
  • Non Small Cell Lung Cancer Metastatic
  • +2 more
  • (no location specified)
Aug 11, 2023

Non Small Cell Lung Cancer, Stage IV NSCLC, Brain Metastases Trial in Hangzhou (Hypofractionated Stereotactic Radiotherap)

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Hypofractionated Stereotactic Radiotherap
  • Hangzhou, China
    Kaicheng Pan
Oct 18, 2022

NSCLC Trial in Guangzhou (Unity-based MR-Linac guided FSRT)

Recruiting
  • Non-small Cell Lung Cancer
  • Unity-based MR-Linac guided FSRT
  • Guangzhou, Guangdong, China
    Hui Liu
Nov 25, 2022

Circulating Tumor DNA and T Cell Repertoire Predict

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Brain Metastases
  • Whole-brain radiotherapy
  • Wuhan, Hubei, China
    Union hospital
Feb 12, 2023

Non-squamous Non-small-cell Lung Cancer, Brain Metastases Trial in Guangzhou (Camrelizumab, Pemetrexed, Carboplatin)

Active, not recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • Brain Metastases
  • Guangzhou, Guangzhou, China
    Li-Kun Chen
Nov 13, 2022

NSCLC, Brain Tumors Trial (bevacizumab, First-Line Chemotherapy Agents, Second-Line Chemotherapy Agents)

Completed
Has Results
  • Non-Small Cell Lung Cancer
  • Brain Neoplasms
  • (no location specified)
Dec 9, 2022

Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Tumor in the Brain, Stage IV Lung Cancer AJCC v8 Trial in Duarte

Not yet recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +2 more
  • Biospecimen Collection
  • +4 more
  • Duarte, California
    City of Hope Medical Center
May 1, 2023

Brain Metastases, Nonsmall Cell Lung Cancer Stage III Trial in Winston-Salem (MRI of the Brain, Blood draws, Quality of Life

Not yet recruiting
  • Brain Metastases
  • Nonsmall Cell Lung Cancer Stage III
  • MRI of the Brain
  • +2 more
  • Winston-Salem, North Carolina
    Wake Forest Baptist Comprehensive Cancer Cente
Jan 19, 2023

NSCLC, EGFR Activating Mutation, Brain Metastases Trial in Beijing (TY-9591, Osimertinib)

Not yet recruiting
  • NSCLC
  • +2 more
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospitial,Chinese Academy of Medic
Jul 9, 2023

Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult Trial (Patritumab deruxtecan)

Not yet recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Patritumab deruxtecan
  • (no location specified)
May 9, 2023

Non-squamous NSCLC Trial in Guangzhou (FSRT combined with Bevacizumab)

Active, not recruiting
  • Non-squamous Non-small Cell Lung Cancer
  • FSRT combined with Bevacizumab
  • Guangzhou, China
    Sun Yat-sen University
Nov 25, 2022

Metastatic Malignant Tumor in the Brain, Stage IV NSCLC AJCC v7 Trial in Houston (procedure, biological, other, radiation)

Recruiting
  • Metastatic Malignant Neoplasm in the Brain
  • Stage IV Non-Small Cell Lung Cancer AJCC v7
  • Cognitive Assessment
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 12, 2022

NSCLC Stage II, Bevacizumab, Immunotherapy Trial in Guangzhou (Serplulimab combined with bevacizumab and first-line chemo)

Not yet recruiting
  • Non-small Cell Lung Cancer Stage II
  • +3 more
  • Serplulimab combined with bevacizumab and first-line chemotherapy
  • Guangzhou, Guangdong, China
    Likun Chen
Apr 10, 2023

Brain Metastases, Non Small Cell Lung Cancer Trial in Durham (Stereotactic Radiosurgery, Immunotherapy)

Recruiting
  • Brain Metastases
  • Non Small Cell Lung Cancer
  • Durham, North Carolina
    Duke Cancer Center
Jun 6, 2022

NSCLC, Non-small Cell Carcinoma, Histiocytic Tumor Trial (BDTX-4933)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +32 more
  • (no location specified)
Mar 30, 2023

Brain Metastases, NSCLC Trial in Shanghai (EGFR-TK Inhibitor, Stereotactic radiotherapy)

Recruiting
  • Brain Metastases
  • Non-small Cell Lung Cancer
  • EGFR-TK Inhibitor
  • Stereotactic radiotherapy
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 27, 2023

Clear-Cell Metastatic Renal Cell Carcinoma, Non Small Cell Lung Cancer Metastatic, Brain Metastases, Adult Trial in Montreal,

Active, not recruiting
  • Clear-Cell Metastatic Renal Cell Carcinoma
  • +4 more
  • Montreal, Quebec, Canada
  • +3 more
Aug 2, 2022

NSCLC, NSCLC Trial in Miami, Cleveland (Osimertinib)

Active, not recruiting
  • NSCLC
  • Non-small Cell Lung Cancer
  • Miami, Florida
  • +1 more
Nov 8, 2022

Brain Metastases From NSCLC Trial (Stereotactic Radiation Therapy, Durvalumab)

Not yet recruiting
  • Brain Metastases From Non-small Cell Lung Cancer
  • (no location specified)
May 24, 2022

Lung Cancer, Lung Cancer Metastatic, Brain Metastases Trial in Sacramento ([18F]-avß6-BP)

Recruiting
  • Lung Cancer
  • +3 more
  • Sacramento, California
    The University of California Davis Comprehensive Cancer Center
Aug 3, 2022

Brain Metastases, Adult, Non Small Cell Lung Cancer, Breast Cancer Trial in Messina, Rome, Turin (Silibinin, Placebo)

Recruiting
  • Brain Metastases, Adult
  • +2 more
  • Silibinin
  • Placebo
  • Messina, Italy
  • +4 more
Jan 9, 2023

Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in

Recruiting
  • Non-small Cell Lung Cancer Metastatic
  • Brain Metastases
  • Radiotherapy combined with PD-1 inhibitors
  • Changsha, Hunan, China
    Xiangya Hospital, Central South University
Nov 27, 2022